EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access

GLP ‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation

Hao Dai iD, Rotana M Radwan, Grant D Scheiffele, Huilin Tang, Amy Sheer, Hsin-Yueh Lin, Pengyue Zhang, Darlene Adirika, Kate Luong, Jiang Bian, Jingchuan Guo

Obesity · 2026-09 · 34 (S2) · 88-100

DOI: 10.1002/oby.70024 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Obesity, online erschienen am 15.09.2025. Verfasst von Hao Dai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hospitalization, Substance-Related Disorders, Hypoglycemic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), approved for type 2 diabetes (T2D) and obesity, may modulate reward pathways and reduce substance‐related behaviors. This study assessed the association between GLP‐1RA use and substance use‐related hospitalization in older adults with coexisting T2D and substance use disorders (SUD).

Methods

A retrospective cohort study using 2016–2020 Medicare data compared GLP‐1RA initiators with new users of SGLT2 inhibitors (SGLT2is) or DPP‐4 inhibitors (DPP4is) among adults aged ≥ 65. The primary outcome was hospitalization for any SUD; secondary outcomes included hospitalizations for alcohol use disorder (AUD) and opioid use disorder (OUD). Propensity score 1:1 matching and Cox proportional hazards models were used under an intention‐to‐treat approach.

Results

In the GLP‐1RA versus DPP4i cohort ( n = 4920), GLP‐1RA users had a lower risk of SUD hospitalization (HR 0.76; 95% CI, 0.67–0.86) and OUD hospitalization (HR 0.64; 95% CI, 0.43–0.96), with a nonsignificant trend for AUD (HR 0.76; 95% CI, 0.53–1.08). No significant differences were observed compared to SGLT2is ( n = 4620).

Conclusions

Among older adults with T2D, GLP‐1RA use was associated with reduced SUD‐related hospitalization versus DPP4i use, suggesting potential repurposing for SUD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HospitalizationSubstance-Related DisordersHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsRetrospective StudiesMedicareUnited StatesRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsRisk FactorsPropensity ScoreProportional Hazards ModelsAlcoholismOpioid-Related DisordersHumansMaleFemaleAged

Stichwörter der Autor:innen

glucagon‐like peptide 1 (GLP‐1)older adultssubtance use disordertype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
  • College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Regenstrief Institute, Indianapolis, Indiana, USA.

ORCID-Profile: Hao Dai

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Dai, H., Radwan, R. M., Scheiffele, G. D., Tang, H., Sheer, A., Lin, H. Y., Zhang, P., Adirika, D., Luong, K., Bian, J., & Guo, J. (2026). GLP ‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation. Obesity, 34(S2), 88-100. https://doi.org/10.1002/oby.70024

Vancouver

Dai H, Radwan RM, Scheiffele GD, Tang H, Sheer A, Lin HY, et al. GLP ‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation. Obesity. 2026;34(S2):88-100. doi:10.1002/oby.70024

BibTeX
@article{Dai2026,
  author = {Dai, Hao and Radwan, Rotana M and Scheiffele, Grant D and Tang, Huilin and Sheer, Amy and Lin, Hsin-Yueh and Zhang, Pengyue and Adirika, Darlene and Luong, Kate and Bian, Jiang and Guo, Jingchuan},
  title = {GLP ‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {S2},
  pages = {88--100},
  doi = {10.1002/oby.70024}
}
Kostenlos starten →